The ubiquitin pathway: An emerging drug target in cancer therapy

被引:35
作者
Ande, Sudharsana Rao [2 ]
Chen, Junjie [3 ]
Maddika, Subbareddy [1 ,3 ]
机构
[1] Inst Life Sci, Hyderabad 500046, Andhra Pradesh, India
[2] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada
[3] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA
基金
美国国家卫生研究院;
关键词
Ubiquitin; E3; ligase; Proteosome; Deubiquitinases; Inhibitors; Cancer therapy; ACTIVE PROTEASOME INHIBITOR; SMALL-MOLECULE ANTAGONISTS; X-LINKED INHIBITOR; PROTEIN-DEGRADATION; ACTIVATING ENZYME; PROSTATE-CANCER; LIGASE ACTIVITY; P53; PATHWAY; DNA-DAMAGE; E3; LIGASE;
D O I
10.1016/j.ejphar.2009.08.042
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ubiquitination is a highly ordered multistep enzymatic process, carried out by a well-defined systematic ubiquitin pathway, which is required for maintaining appropriate levels and functional activities of various cellular proteins. Targeted regulation of proteins by ubiquitin pathway controls numerous cellular processes including cell proliferation, signal transduction, apoptosis, transcriptional regulation, receptor modulation as well as endocytosis. Significant progress has been made in recent years in not only understanding the structure, function and important regulatory roles of ubiquitin network but also the alterations of ubiquitin pathway in various human diseases including cancer. Based on the progress made, it is now possible to target specifically various components involved in the ubiquitin pathway such as E3 ubiquitin ligases, deubiquitinases and proteosome for potential anticancer therapies. Here we review the potential drug targets available in the ubiquitin system and the small molecule inhibitors that can target these components in the pathway, which can be developed into novel anticancer therapeutics in the near future. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:199 / 205
页数:7
相关论文
共 61 条
[1]   Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ [J].
Arnt, CR ;
Chiorean, MV ;
Heldebrant, MV ;
Gores, GJ ;
Kaufmann, SH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (46) :44236-44243
[2]   The HECT family of E3 ubiquitin ligases: Multiple players in cancer development [J].
Bernassola, Francesca ;
Karin, Michael ;
Ciechanover, Aaron ;
Melino, Gerry .
CANCER CELL, 2008, 14 (01) :10-21
[3]   MDM2 is a central node in the p53 pathway: 12 years and counting [J].
Bond, GL ;
Hu, WW ;
Levine, AJ .
CURRENT CANCER DRUG TARGETS, 2005, 5 (01) :3-8
[4]   Ubiquitination and deubiquitination of PCNA in response to stalling of the replication fork [J].
Brown, Stephanie ;
Niimi, Atsuko ;
Lehmann, Alan R. .
CELL CYCLE, 2009, 8 (05) :689-692
[5]   The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications [J].
Burger, AM ;
Seth, AK .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (15) :2217-2229
[6]   A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib [J].
Chauhan, D ;
Catley, L ;
Li, GL ;
Podar, K ;
Hideshima, T ;
Velankar, M ;
Mitsiades, C ;
Mitsiades, N ;
Yasui, H ;
Letai, A ;
Ovaa, H ;
Berkers, C ;
Nicholson, B ;
Chao, TH ;
Neuteboom, STC ;
Richardson, P ;
Palladino, MA ;
Anderson, KC .
CANCER CELL, 2005, 8 (05) :407-419
[7]   ATP-DEPENDENT CONJUGATION OF RETICULOCYTE PROTEINS WITH THE POLYPEPTIDE REQUIRED FOR PROTEIN-DEGRADATION [J].
CIECHANOVER, A ;
HELLER, H ;
ELIAS, S ;
HAAS, AL ;
HERSHKO, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (03) :1365-1368
[8]   The ubiquitin system: pathogenesis of human diseases and drug targeting [J].
Ciechanover, A ;
Schwart, AL .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2004, 1695 (1-3) :3-17
[9]  
CIECHANOYER A, 1980, J BIOL CHEM, V255, P7525
[10]   Disruption of HAUSP gene stabilizes p53 [J].
Cummins, JM ;
Rago, C ;
Kohli, M ;
Kinzler, KW ;
Lengauer, C ;
Vogelstein, B .
NATURE, 2004, 428 (6982) :1-2